Objective:To compare effects of Lenalidomide and Cyclophosphamide in treatment of patients with multiple myeloma.Methods:The clinical data of 112 patients with multiple myeloma admitted to the hospital from 2019 to 2022 were retrospectively analyzed.According to different treatment methods,they were divided into control group(n=53)and study group(n=59).Both groups were treated with Bortezomib and Dexamethasone.On this basis,the control group was treated with Cyclophosphamide,while the study group was treated with Lenalidomide capsules.The clinical efficacy,the incidence of adverse reactions,and the treatment cost were compared between the two groups.Results:The high-quality remission rate of the study group was 62.71%(37/59),which was higher than 35.85%(19/53)of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total remission rate between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The total cost and the ratio of total cost to effect of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).Conclusions:On the basis of Bortezomib and Dexamethasone treatment,Lenalidomide can improve the high-quality remission rate in patients with multiple myeloma,which is better than Cyclophosphamide treatment,but the treatment cost needs to be increased.
维普
万方数据